Yinhu Qingwen Granule in the Treatment of Viral Pneumonia

• Status: Not yet recruiting
• Trial end date: 2022-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a non-randomized single arm clinical study to observe the effect of Yinhu Qingwen Granule in the relief of fever and improvement of related-symptoms of patients with viral pneumonia.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhong Wang

Criteria

Inclusion Criteria:

• Clinical diagnosis of viral pneumonia;

• Clinical diagnosis of Shi-du-yun-jie Zheng (damp stagnation syndrome) according to Chinese medicine, including fever,cough,sore throat,stuffy chest,irritability and thirst,short yellow urine,constipation or loose stool,thick and greasy yellow coating,and slippery pulse;

• Chest CT showed signs of acute exudative pneumonia in the lungs;

• Over 18 years old, regardless of gender, voluntarily signed an informed consent form;

• Those who were hospitalized and were accompanied by fever (body temperature ≥37.3℃) and respiratory tract symptoms like cough or dyspnea, when they were enrolled.

Exclusion Criteria:

• Patients that are susceptible to sensitivity or known to be allergic to the study drug;

• Patients whose white blood cell count ≥12×10^9 or neutrophil percentage ≥80%;

• Patients whose weight is less than 40 kg;

• Patients with respiratory failure or need mechanical ventilation;

• Patients with shock;

• Patients required to be in ICU monitoring and treatment;

• Patients participated in other clinical trials within 1 month;

• Patients with known renal impairment;

• Patients with any of the following laboratory parameter abnormalities during the screening period or within 24 hours before screening: ALT or AST level> 5 times the upper limit of normal range (ULN) or-ALT or AST level > 3 times ULN and total bilirubin level> 2 times ULN;

• Patients with immune system diseases and long-term use of immunosuppressive agents;

• Pregnant or breastfeeding women, or who have a positive pregnancy test during the screening period, or plan to become pregnant within 3 months after the study treatment.